For investors
Biotica Bio supports investment and portfolio teams with evidence-led due diligence and strategy.
What we offer
- Target due diligence — Structured assessment of biology, disease association, druggability, and safety so you can move at deal speed without sacrificing rigour.
- Pipeline and portfolio review — Prioritisation and evidence context across targets or indications for portfolio decisions.
- New area screening — Fast, reproducible scans of therapeutic areas or target classes using the same Open Targets evidence base.
- Reproducibility — Same query, same data; you can re-run or audit as evidence updates or share methodology with co-investors.
- No conflict — We do not invest; our only deliverable is the assessment and narrative.
- Enterprise-ready framing — Outputs can be used by venture, corporate strategy, and operating leaders evaluating payer/provider-adjacent opportunities.
The Open Targets Platform aggregates and scores target–disease evidence from dozens of curated and experimental sources—the same data that supports target validation across industry and academia. We turn that into decision-ready output for your process.
Who this is for
- VC, crossover, and PE-backed life sciences investment teams.
- Portfolio support teams needing reproducible scientific reviews.
- Investment committees requiring concise, auditable evidence packages.
- Strategic healthcare venture teams requiring clinical, commercial, and adoption-aware diligence.
Common investor outcomes
- Faster go/no-go decisions with clearer biological downside cases.
- Better portfolio prioritisation across multiple targets or indications.
- Stronger investment memos with transparent evidence provenance.
See a representative example report, review methodology, or request scoped diligence support.
For deeper strategic context, see investor-oriented sector notes and the diligence memo framework.
For leadership and operating context behind this approach, see John Round’s venture operator profile.